ANI Acquisition Leads to Alimera Sciences Shares Jump

By acquiring Alimera Sciences, ANI Pharmaceuticals is expanding its presence in the rare illness market.

Alimera’s share price surged by 77% after the $381 million deal was announced. It is anticipated that the transaction would conclude in Q3 of 2024.

According to ANI CEO Nikhil Lalwani, projected 2024 revenues from the Alimera acquisition will increase by $105 million. Additionally, the business projects significant increase in adjusted profits per share starting in 2025 and accretion in the high single to low double digits afterward. ANI plans to use borrowed funding in addition to its own funds on hand to complete the deal. It has secured committed funding of $280 million from Blackstone Credit & Insurance and J.P. Morgan.